In a nutshell This study compared the risk of severe hypoglycemia (dangerously low blood glucose levels) with insulin glargine-100 (Lantus) and insulin glargine-300 (Toujeo) for patients with type 1 diabetes (T1D). It found that both medications improved glucose control, and insulin glargine-300 had a lower risk of hypoglycemia. Some background T1D is...
Read More
In a nutshell This study looked at whether iGlarLixi (Soliqua), a combination of long-acting insulin glargine (Lantus) and lixisenatide (Lyxumia), can improve glucose control for patients with type 2 diabetes (T2D) uncontrolled with long-acting insulin alone. It found that iGlarLixi improved overall and after-meal blood sugar control compared to insulin...
Read MoreIn a nutshell The aim of this study was to investigate blood glucose control and rates of hypoglycemia (dangerously low blood glucose levels) when diabetic patients were switched from their basal insulin to insulin degludec (Tresiba). The main finding of this study was that patients who were switched to insulin degludec had improved blood glucose control...
Read More
